| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H17NO5 |
| Molecular Weight | 327.3313 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(\C=C\C(=O)NC2=C(C=CC=C2)C(O)=O)C=C1OC
InChI
InChIKey=NZHGWWWHIYHZNX-CSKARUKUSA-N
InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
| Molecular Formula | C18H17NO5 |
| Molecular Weight | 327.3313 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. Tranilast is used for the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
CNS Activity
Originator
Approval Year
Cmax
AUC
T1/2
Sample Use Guides
In general, for dosage regimen: For adults, take 1 capsule (100 mg of the active ingredient) at a time, 3 times a day. The dosage should be adjusted according to the disease, age or symptoms.
Route of Administration:
Oral
Tranilast suppressed the production of PGD2 in a dose-dependent manner with an IC50 of 0.1 mM in rat peritoneal mast cells. The glutathione-dependent conversion of [14C]PGH2 to PGD2 by PGD synthetase (PGH-D isomerase, EC 5.3.99.2) was inhibited by Tranilast, with 50% inhibition achieved at 0.08 mM in broken cell preparations of rat peritoneal mast cells.
